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Abstract
Background: An early detection of Osteoarthritis is urgently needed and still not possible until today. The aim of
the study was to assess whether molecular biomarkers of cartilage turnover are associated with longitudinal change
in knee cartilage thickness during a 2 year period in individuals with increased risk of developing knee
osteoarthritis. A secondary aim was to assess whether prior knee injury or subjective patient-reported outcomes at
baseline (BL) were associated with articular cartilage changes. Nineteen volleyball players (mean age 46.5 ± 4.9 years,
47% male) with a 30-year history of regular high impact training were recruited. The serum biomarkers Cpropeptide
of type II procollagen (CPII), cartilage oligomeric matrix protein (COMP), collagenase generated carboxy-terminal
neoepitope of type II collagen (sC2C), cartilage intermediate layer protein 2 (CILP-2), and the urine biomarkers C-
telopeptide of type II collagen (CTX-II) and collagenase-generated peptide(s) of type II collagen (C2C-HUSA) were
assessed at BL and at 2 year follow up (FU). Femorotibial cartilage thinning, thickening and absolute thickness
change between BL and FU was evaluated from magnetic resonance imaging. Subjective clinical status at BL was
evaluated by the International Knee Documentation Committee Subjective Knee Form and the Short-Form 36
Physical Component Score.
Results: CILP-2 was significantly higher at FU and linearly associated with the absolute cartilage thickness change
during the experimental period. Prior injury was a predictor of increased absolute cartilage thickness change.
Conclusion: Measuring the change in the cartilage biomarker CILP-2 might be a valid and sensitive method to
detect early development of knee osteoarthritis as CILP-2 appears to be related to cartilage thickness loss in certain
individuals with increased risk of developing knee osteoarthritis. Prior knee injury may be predictive of increased
articular cartilage thickness change.
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Background
Using current standard diagnostics, i.e. radiographic as-
sessment, knee osteoarthritis (OA) is diagnosed at a rela-
tively late stage of the disease when the knee joint is
characterized by substantial cartilage changes (e.g. nar-
rowing of the knee joint space and osteophyte forma-
tion). By this time, patients often suffer from functional
impairments and pain (Kraus et al., 2011). Use of con-
servative treatment may have limited impact due to the
severity of the disease at this point and surgery is often
required (Buttgereit et al., 2015). Recent observations of
young athletes with high risk of developing knee OA
(Boeth et al., 2017a) emphasize the importance of valid,
reliable and sensitive methods to detect development of
knee OA prior to presentation of severe structural path-
ology (Garnero et al., 2000, Guermazi et al., 2011, Roe-
mer and Guermazi 2014).
While the progression of OA may be driven by cartil-
age factors in some patients, it may be driven by bone or
inflammation associated factors in others (Buttgereit et
al., 2015). Metabolic alterations in joint tissues associ-
ated with different stages of incident OA involve
changes in both the synthesis and degradation of skeletal
matrix molecules (Kong et al., 2006, Cibere et al., 2009).
Previous observations suggest that several molecular
biomarkers of cartilage turnover may be helpful in iden-
tifying individuals at risk of joint degradation (Vignon et
al., 2001, Boeth et al., 2017a, b, Kraus et al., 2017). The
serum cartilage type II collagen synthesis biomarker
carboxy-propeptide of type II procollagen (CPII) is in-
versely associated with risk of having radiographically
defined knee OA (Nelson et al., 1998, Cibere et al.,
2009). In addition, serum levels of cartilage oligomeric
matrix protein (COMP), which binds and stabilizes type
II collagen fibers, are positively associated with the se-
verity of radiographically assessed knee OA (Clark et al.,
1999, Vilim et al., 2001, Rousseau and Delmas 2007).
When assessed by magnetic resonance imaging (MRI),
knee joint degeneration and OA are associated with
serum levels of both COMP and the collagenase gener-
ated carboxy-terminal neoepitope of type II collagen
(C2C) (King et al., 2004, Hunter et al., 2007). Further-
more, the C-telopeptide of type II collagen (CTX-II),
which is often used as an urine biomarker of articular
cartilage degradation, is elevated in OA patients com-
pared to controls (Christgau et al., 2001) and associated
with the risk (Cibere et al., 2009) and severity of radio-
graphically defined OA (Christgau et al., 2001, Reijman
et al., 2004, Jordan et al., 2006), as well as with MRI di-
agnosed knee cartilage defects (Ding et al., 2005). The
collagenase-generated peptide of human type II collagen
(C2C-HUSA) assay is predictive of early onset knee OA
and its progression (Poole et al., 2016). Finally, serum
levels of cartilage intermediate layer protein 2 (CILP-2)
have been observed to be reduced in a model of mur-
ine OA (Bernardo et al., 2011). The fact that the
intermediate zone of healthy adult articular cartilage
is particularly enriched with this protein, suggests that
changes in CILP-2 may be associated with the pro-
gression of arthritis.
While most previous studies on the role of molecular
biomarkers in knee cartilage changes have included pa-
tients with radiographically diagnosed knee OA, only
few studies have investigated this relationship in individ-
uals with an increased risk of developing OA, such as
athletes performing high impact sports (Roos et al.,
1995, Matsumoto et al., 1997, Creighton et al., 2001,
O'Kane et al., 2006, Hoch et al., 2012, Mateer et al.,
2015, Boeth et al., 2017b). To our knowledge no previ-
ous study has investigated the longitudinal association
between molecular biomarkers of cartilage turnover and
cartilage thickness changes in such at risk population. In
a previous study, we observed significant decrease in
knee joint cartilage thickness across a 2 year period in
adult former volleyball athletes (Eckstein et al., 2014).
However, for this population the potential for using mo-
lecular biomarkers of cartilage turnover as predictors of
knee cartilage turnover and the possible future develop-
ment of knee OA is unknown.
The primary aim of the present study was to assess
whether cartilage biomarkers were associated with knee
cartilage thickness change during a 2 year period in indi-
viduals with increased risk of developing knee OA. A
secondary aim was to assess whether prior knee injury
or subjective patient-reported outcomes at baseline (BL)
were associated with cartilage thickness changes. We in-
cluded athletes with a rigorous training history of high
impact activities as a model for individuals with a high
risk of developing knee OA (Kujala et al., 1994).
Methods
Subjects
Nineteen adult former national level volleyball players
(10 females/9 males) over the age of 40 years were in-
cluded in the present study (Table 1) after giving written
informed consent to the experimental procedure, which
was approved by the local ethics committee (EA2/055/
10) and in accordance with relevant guidelines and regu-
lations. The subjects were assessed at BL and after a 2
year follow up (FU) period. All subjects had a history of
Table 1 Subject demographics (N = 19)
Mean ± standard deviation
Age (years) 46.5 ± 4.9
Body mass (kg) 82.3 ± 16.2
Body height (cm) 183 ± 8.9
BMI (kg/m2) 24.3 ± 2.9
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participating in volleyball at a German national level
since their adolescence and had completed structured
volleyball training at least twice a week throughout their
career. No instructions were given to alter the intensity
or load of the training schedule during participation in
the study. At the time of inclusion, all subjects were
evaluated for knee injuries that required surgical inter-
vention prior to the study. Exclusion criteria were injur-
ies within 1 year prior to BL. In total, 8 of the included
subjects had prior knee surgery greater than 1 year prior
to BL. Of the males, 1 had a lateral meniscectomy, 1 had
lateral and medial meniscectomies and articular cartilage
debridement, 1 had other knee surgery, and 1 had cartil-
age debridement and meniscus surgery. Of the females,
1 had nerve transection and cartilage debridement, 1 had
knee arthroscopy, 1 had meniscus surgery, and 1 had a
medial meniscectomy. None of the included subjects
were radiographically diagnosed with knee OA. All ex-
periments were performed in accordance with relevant
guidelines and regulations.
Clinical outcome scores
To assess the subjective clinical status at BL, the subjects
completed the Subjective Knee Form of the International
Knee Documentation Committee (IKDC) and the
Short-Form 36 (SF-36). The IKDC is a validated
patient-rated outcome measure that evaluates symptoms,
function, and sports activity in patients with knee prob-
lems (Irrgang et al., 2001). The SF-36 is a validated metric
for general health outcomes (Patel et al., 2007). Only the
Physical Component Score (SF-36 PCS) was assessed. For
each outcomes measure, scores range from 0 to 100 with
a lower score indicating greater disability.
Molecular biomarkers analyses
Blood samples were obtained following an overnight fast
and urine samples were collected on the second morn-
ing void. Samples were collected at both BL and FU after
MRI scans were completed, prior to which the subjects
had been inactive for 45 min. Due to an inadequate
blood sample at BL in one subject, serum samples were
obtained from 18 subjects at BL and 19 subjects at FU.
Urine samples were obtained from all subjects at both
BL and FU. Serum and urine samples were immediately
stored at − 70 °C until testing. The samples were frozen
on dry ice and transported to AnaMar AB (Lund,
Sweden) and IBEX Pharmaceuticals (Montreal, Quebec,
Canada) for testing.
The analysis of serum cartilage molecular biomarkers
involved the following assays: COMP (expressed in U/L),
CILP-2 (expressed in ng/mL), sC2C (expressed in ng/
mL), and CPII (expressed in ng/mL). Urine biomarkers
C2C-HUSA and CTX-II are expressed as ng/mmol of
creatinine. CTX-II was supplied by Immunodiagnostic
Systems Ltd., Boldon, UK. At IBEX Pharmaceuticals, all
samples were assayed in duplicate for sC2C, CPII,
C2C-HUSA and CTX-II and urine creatinine. At Ana-
Mar AB, all the samples were assayed in duplicate for
COMP and CILP-2. All subjects were randomly assigned
to the assay plates. Both time points for each subject
were always assayed on the same plate. All analyses were
conducted blinded, without prior knowledge of the iden-
tity of individual samples. Commercially available assays
(all assays except CILP-2) were performed as directed by
the manufacturer in accordance with their published
guidelines that accompany the assay kits.
Serum cartilage matrix and degradation biomarkers
COMP was measured using a sandwich enzyme-linked im-
munosorbent assay (ELISA) (AnaMar AB), CILP-2 using
an in-house research competitive ELISA (AnaMar AB), and
the cartilage collagen degradation biomarker C2C using a
competitive inhibition ELISA (IBEX Technologies).
Serum cartilage collagen synthesis biomarker
CPII was assayed using a competitive inhibition ELISA
(IBEX Technologies).
Urine cartilage type II collagen degradation biomarkers
C2C-HUSA was assessed using a new sandwich assay
(IBEX Technologies,) (Poole et al., 2016) and CTX-II
was assessed using a competitive assay (CartiLaps; IDS).
The level of creatinine was measured using an enzymatic
colorimetric kit (QuantiChrom™; BioAssay Systems,
Hayward, CA, USA). Additionally, to assess the relative
balance between type II collagen matrix synthesis and
degradation, the following ratios were calculated: sC2C/
CPII, C2C-HUSA/CPII, and CTX-II/CPII (Nelson et al.,
1998, Cibere et al., 2009).
All assays, with the exception of CILP-2, had an
inter-assay variability of 2–3%, intra-assay variability of
2–4%, and recovery of 93–116% (for further details
please visit the websites of the manufacturers at www.
ibex.ca). The CILP-2 competitive assay had an
intra-assay variation of 11.1% and the inter-assay varia-
tions for high control was 20.7% and for low control
22.2%. For the competitive CILP-2 assay, microtitre
plates (Costar high binding 9018) were coated with a 61
amino acid long synthetic polypeptide from the CILP2
domain 1 (V551-D611 (UniProt Q8IUL8) Schafer-N,
Copenhagen, Denmark). Plates were incubated at room
temperature overnight. Plates were washed with
PBS-Tween (PBS-T, Medicago) 4 times and incubated
with block solution (1% Probumin from Millipore in
PBS-T) for 2–3 h. Standard (range 100 ng/ml-0.14 ng/
ml) and athlete serum samples were diluted 1:10 in con-
jugate buffer (Medicago 25–0142+ 0.1 mg/ml goat IgG
from Sigma) and pre-incubated with HRP-coupled
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anti-CILP-2 antibody (polyclonal affinity-purified goat
antibody (Capra Science, Sweden) against the coating
CILP-2 peptide) on non-binding plates (U96 PP 0.5 ml,
Natural, Thermo Scientific) for 1 h. The blocked plates
were washed with PBS-T 4 times and the pre-incubated
sample was transferred to the freshly washed plates
followed by further incubation at room temperature for
2 h. After washing with PBS-T (6 times) TMB substrate
(Medicago) was added and the signal allowed developing
for 20 min protected from light. The reaction was
stopped by the addition of 0.5M H2SO4 before reading
the plates at 450 nm. The CILP-2 assay standard, a 16
kDa protein (His6tagged aa C206-P246 merged with
V551-D611) was produced in E. coli and IMAC/Ni2+ col-
umn purified. Standard curve was produced by spiking
standard protein to non-detecting CILP-2 serum.
Analysis of articular cartilage thinning and thickening
MRI of the dominant knee was performed at BL and FU.
A sagittal 3D VIBE sequence with water excitation (1.5
mm slice thickness; 0.31mm in-plane resolution, repeti-
tion time = 14.6ms, echo time = 6.5ms, flip angle = 20°)
was used for quantitative analysis of articular cartilage
thickness. MRI analysis was performed by an expert
reader with 12 years of experience in musculoskeletal
image analysis who was blinded to the acquisition order.
Segmentation of the subchondral bone and cartilage
surface area of the medial and lateral tibia and
weight-bearing medial and lateral femoral condyle was
performed as described earlier, with all segmentations be-
ing quality-controlled by an expert reader (Eckstein et al.,
2014). Overall femorotibial changes in articular cartilage
thickness between BL and FU were determined from 16
femorotibial subregions, with the location-independent
change (thinning and thickening) scores being reported
(Wirth and Eckstein 2008, Wirth et al., 2016, Eckstein et
al., 2017). The absolute change in cartilage thickness was
computed from the changes observed across 16 femoroti-
bial cartilage subregions within each knee by summing the
absolute subregional changes (i.e. both greater increase
and decrease in subregional cartilage thickness result in a
greater absolute thickness change) (Eckstein et al., 2015a,
Eckstein et al., 2017).
Statistics
In order to fulfil the primary aim of the study, two steps
were conducted. First, the differences between BL and
FU values of the four serum and the two urine bio-
markers and the three ratios (sC2C/CPII, C2C-HUSA/
CPII, and CTX-II/CPII) were established using paired
Student’s t-test. In case of a significant difference be-
tween BL and FU, effect size was calculated using
Cohen’s d (Rosenthal 1991). The effect size was consid-
ered large when d = 0.8, medium when d = 0.5 and small
when d = 0.2. Secondly, variables with a significantly dif-
ferent FU value compared to the BL were included in a
linear regression analysis to establish the relationship be-
tween changes in molecular biomarkers and absolute
(location independent) cartilage thickness change. To
fulfill the second aim of the study, a backward stepwise
multiple linear regression analysis (removal criteria of
p ≥ 0.10) was performed with total cartilage change as a
dependent variable and prior injury requiring surgery
(yes/no), IKDC score and SF-36 PCS score as independ-
ent variables. Assumptions of normal distribution, lin-
earity and homoscedasticity of the total cartilage change
variable were confirmed after visual inspection of the
distribution histogram and a plot of the standardized re-
siduals as a function of the standardized predicted
values. Level of significance was set at 0.05. All statistical
calculations were performed in SPSS (IBM SPSS Statis-
tics, version 24, 2016, USA).
Results
When comparing serum and urine biomarkers at BL and
FU, CILP-2 was significantly lower at BL (Fig. 1a, p = 0.017,
effect size = 0.60). No other significant changes in molecu-
lar biomarkers from BL to FU were observed (Figs. 1b-d
and 2). No significant differences were observed in the deg-
radation/synthesis ratios between BL and FU (Fig. 3). The
linear regression analysis revealed a significant linear
relationship between CILP-2 change and absolute car-
tilage thickness change (Fig. 4, F(1,16) = 5.557, p =
0.031, r = 0.508, r2 = 0.258, adj. r2 = 0.211, unstandard-
ized B coefficient (95% confidence interval) = 0.141
(0.014–0.268), standardized β coefficient = 0.508). The
absolute contribution of cartilage thickness loss and
gain to the total cartilage change for each subject is
presented in Fig. 5. Cartilage thickness loss was the lar-
gest contributor to the total cartilage change for the
majority of subjects. Figure 6 shows full thickness car-
tilage damage of one adult subject (A) and another
adult subject without any cartilage lesions (B) using sa-
gittal 3D VIBE MRI.
The BL mean ± SD IKDC and SF-36 PCS score were
94.3 ± 8.6 and 53.4 ± 2.5, respectively. The stepwise mul-
tiple regression analysis removed first the IKDC and then
the SF36 variable from the model leaving only previous in-
jury requiring surgery as a predictor of total cartilage
changes. This model was significant (F(1,17) = 7.140, p =
0.016, r = 0.54, r2 = 0.296, adj. r2 = 0.254, unstandardized B
coefficient (95% confidence interval) = 0.613 (0.129–
1.097), standardized β coefficient = 0.544).
Discussion
This study is the first to investigate long-term changes
in cartilage molecular biomarkers in middle aged indi-
viduals with increased risk of developing knee OA.
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Serum and urine biomarkers of cartilage degeneration
and synthesis were included to provide potential associa-
tions between longitudinal changes in molecular bio-
markers and knee cartilage thickness change. This study
used volleyball players with a considerable history of
high impact training as a model for a high-risk group.
None of the included subjects were radiographically di-
agnosed with knee OA at the time of the study. How-
ever, it has previously been suggested that high level
athletes in weight bearing sports have an increased risk
for developing OA in lower extremity joints (Kujala et
al., 1994). Using this experimental model, our primary
aim was to assess whether molecular biomarkers of
cartilage turnover were associated with knee cartilage
thickness change during a 2 year period. We observed
that the collagen degeneration serum biomarker CILP-2
was significantly increased with a medium to large effect
size at the end of the 2 year period, and that this change
was linearly related to the increase in total cartilage
change assessed by MRI. Approximately 21% of the vari-
ation in total cartilage change could be explained by the
variation in the change of CILP-2. Furthermore, for the
majority of subjects, the loss of cartilage thickness was
greater than the gain across all subregions. The second-
ary aim of the study was to assess whether prior injury
requiring knee surgery or subjective patient-reported
outcomes were associated with cartilage changes. We
observed that the presence of previous injuries could be
Fig. 1 Mean ± standard deviation levels of serum (CILP-2 (a), COMP (b), sC2C (c) and CPII (d)) biomarkers at baseline and 2 years follow up. NS:
no significant difference between time points
Fig. 2 Mean ± standard deviation levels of urine (C2C-HUSA (a) and CTX-II (b)) biomarkers at baseline and 2 years follow up. NS: no significant
difference between time points
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Fig. 3 Mean ± standard deviation ratios between molecular biomarkers of cartilage degradation and synthesis (sC2C/CPII (a), C2C-HUSA/CPII (b),
CTXII/CPII (c)) at baseline and 2 years follow up. NS: no significant difference between time points
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a predictor for the total cartilage change such that indi-
viduals with prior injuries can be expected to have a
higher level of cartilage change.
The positive association between changes in CILP-2
and total cartilage thickness change, which mainly repre-
sented articular cartilage loss, suggests that increasing
levels of this biomarker coincide with structural progres-
sion towards knee OA. Furthermore, since CILP-2 is
found in articular cartilage and meniscus (Bernardo et
al., 2011), it could be speculated that this biomarker may
be used to detect articular cartilage thickness change fol-
lowing synovial tissue damage from long term regular
high-impact activity (e.g. volleyball). CILP-2 changes in
OA have been little investigated. Tamm and Vija (2015)
observed that patients with radiographically diagnosed
tibiofemoral OA had significantly lower levels of CILP-2
compared to healthy controls and that the CILP-2 de-
creased significantly over a 2 year period in the patients.
Similarly, CILP-2 was observed to be downregulated in
mice with experimental-induced knee OA when cartilage
erosion was apparent (Bernardo et al., 2011). Our data
suggest loss of CILP-2 in the tissue as it goes up in
serum on a long-term scale in adult athletes of a
high-impact sport suggesting release from cartilage. This
could be due to the ongoing cartilage remodeling in re-
sponse to the impact stimulus by the regular training
performed by the athletes.
Several previous studies have investigated the associ-
ation of COMP with the incidence and progression of
OA, emphasizing its potential as a biomarker of OA path-
ology. Dragomir et al. (2002) observed COMP to be posi-
tively associated with pre-radiographic symptoms of hip
OA but not knee OA. Additionally, studies have observed
COMP to be positively associated with the radiographic
severity of hip and knee OA (Clark et al., 1999, Vilim et
al., 2001, Reijman et al., 2004). Furthermore, several stud-
ies have assessed short-term changes in serum levels of
COMP in athletes. Hoch et al. (2012) investigated changes
in COMP in collegiate soccer players during a 3-month
soccer season and observed increased levels at mid- and
post-season compared to preseason. Neidhart et al. (2000)
observed higher BL COMP levels in marathon runners
compared to healthy controls, and that COMP levels in-
creased after completing a marathon. Finally, Kersting et
al. (2005) investigated the relationship between serum
COMP changes and knee cartilage volume changes imme-
diately following 1 hour of running, and observed that an
increase in serum COMP was associated with a decrease
in knee cartilage volume. While these studies suggest that
COMP is positively associated with both acute effects of
high impact activities and short-term exposure to high
volumes of high impact dominated activities, the present
study could not confirm these observations on a
long-term scale. The aforementioned studies on soccer
players and runners included acute (hours) or short-term
(months) increases in activity level and exposure to high
impact stimuli, whereas, the present experimental setup
did not include a deliberate alteration in activity level dur-
ing the 2 years. Furthermore, it is likely that the subjects
in the present study had experienced considerable higher
training loads earlier in their career compared to the
period of the study. Thus, the observed cartilage thickness
change is presumable primarily a result of the accumu-
lated training throughout the careers of the athletes and
not a consequence of alteration in acute or shot-term ac-
tivity/training exposure. This would suggest that only
CILP-2 was able to detect cartilage degradation induced
by years-long exposure to high impact training.
Fig. 4 Linear regression analysis plot of total cartilage change as a
function of change in CILP-2. Dashed lines are ±95% confidence and
95% prediction lines
Fig. 5 Cartilage thickness changes for all subjects. Positive values
indicate cartilage thickness gain and negative values indicate
cartilage thickness loss. The total cartilage change corresponds to
the absolute vertical distance between the triangle and circle for
each subject. The vertical dashed line separates subjects without
previous knee injury (to the left of the line, subject 1–11) and
subjects with previous knee injury (to right of the line, subject 12–19)
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The lack of significant difference between the BL and
FU ratios for the urine type II collagen degradation bio-
marker CTX-II and collagen synthesis biomarker ratio
suggests that these patients remain in a steady state re-
garding the balance between type II collagen degradation
and synthesis. In a no knee OA, early knee OA and ad-
vanced knee OA MRI/biomarker study the uCTX-II/
sCPII ratio was both, prognostic of progression of knee
OA and able to differentiate between these groups
(Cibere et al., 2009). However, this variable has shown
not to be an useful indicator of total cartilage change for
the population studied here. Previously, the ratio for
uC2C/CPII (but not sC2C/sCPII), both not studied here,
was also better than individual biomarkers at distin-
guishing between subjects with pre-radiographically de-
fined and radiographically and MRI defined stages of
knee OA (Cibere et al., 2009). The uC2C-HUSA/CPII
ratio used here has not yet been studied in knee OA
populations.
The scores from the IKDC and SF-36 PCS question-
naires were not found to be predictors of absolute cartil-
age thickness change. This may be due to a lack of
sensitivity in the two questionnaires (e.g. for the IKDC
10 of the 19 subjects achieved a maximum score of 100,
demonstrating a strong ceiling effect). These observa-
tions question the use of these types of subjective mea-
sures to predict cartilage thickness change. In contrast,
the regression model revealed that the presence of a pre-
vious knee injury is a predictor for the absolute cartilage
thickness change observed during the 2 year period.
Thus, the included athletes who had suffered from injur-
ies requiring surgery over 1 year prior to BL were more
likely to have a higher total cartilage change after 2
years. This is supported by previous studies. Eckstein
and colleagues observed an overall thickening of cartil-
age in the tibiofemoral joint during the first 5 years
following ACL rupture, concomitant with localized car-
tilage thinning in posterior subregions of the medial and
lateral tibia (Eckstein et al., 2015b). Although the present
study did not assess subregional differences in cartilage
change, visual inspection of Fig. 5 indicates that for most
of the subjects concomitant overall cartilage thinning
and thickening was observed supporting the previous re-
sults presented by Eckstein et al. (2015b). Additionally,
meniscal tears have been associated with cartilage loss
over 2 years in patients with knee OA (Chang et al.,
2011). Of the eight injured athletes of the present study,
five had meniscal related injuries supporting the link be-
tween this type of injury and greater cartilage turnover.
As previously mentioned, the present study relies on the
assumption that the included athletes constitute a popula-
tion with higher risk of developing knee OA. It is unknown
at what work load, frequency and intensity that healthy
beneficial physical activity becomes a risk factor for devel-
opment of OA. However, the prevalence of former high
level athletes seeking medical treatment for OA later in life
has been observed to be significantly higher compared to
non-athletes (Kujala et al., 1994). Since the risk of sustain-
ing injuries requiring surgery is likely to increase with the
years of participation in volume-high impact training (e.g.
competitive sports on national/international level), it is
possible that the increased risk of OA in athletes is partly
related to them having more severe joint-related injuries
compared to non-athletes. Alternatively, it could be specu-
lated that the combination of a long training history in-
cluding high impact activities and joint injuries requiring
surgery increases the risk for developing OA even more
than the two parameters separately (Wilder et al., 2002,
Teichtahl et al., 2012).
The present pilot study has limitations which need to
be taken into account when interpreting the results. The
relatively low subject number of patients affects both the
Fig. 6 Lateral compartment of male participants with a full thickness cartilage damage of the lateral femur and tibia and b) without cartilage
lesions depicted using sagittal 3D VIBE MRI
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statistical power of the study and increases the risk of
overfitting of the multiple regression model to the data.
Therefore, future studies are needed to increase the
number of subjects and the statistical power to confirm
these preliminary data. Additionally, caution must be
used when extrapolating these findings to other popula-
tions considered at high risk of OA, as our subjects were
drawn from a specific subpopulation of adults who were
prior volleyball athletes. Furthermore, no age-matched
control group was included. Thus, it cannot be excluded
that the observed changes in CILP-2 and total cartilage
change are an effect of aging.
Conclusions
In conclusion, this present study observed that the car-
tilage serum biomarker CILP-2 is related to cartilage
thickness loss in individuals with increased risk of devel-
oping knee OA. Thus, measuring the change in CILP-2
might be a valid and sensitive method to detect early de-
velopment of knee OA. Additionally, the presence of
previous knee injuries requiring surgery was observed to
be a predictor for increased total cartilage change.
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